

Attachment Set A: Harm Reduction References

Table of Contents

#	Item	Pages
A1	AAPHP Resolution and White Paper: The Case for Harm Reduction for control of tobacco-related illness and death , October 26, 2008 (from www.aaphp.org web site).	A1
A2	Rodu B; Phillips CV: Switching to smokeless tobacco as a smoking cessation method: evidence from the 2000 National Health Interview Survey . Harm Reduction Journal 5:18 (2008)	A20
A3	Philips CV: Debunking the claim that abstinence is usually healthier for smokers than switching to a low-risk alternative, and other observations about anti-tobacco-harm-reduction arguments . Harm Reduction Journal 6:29 doi 10-1186/1477-7517-6-29 2009	A28
A4	Nitzkin: J: Promoting Snus Will Save Lives in the USA – an article posted on the Tobacco Issues Page of the www.aaphp.org web site in response to the paper by Zhu et al, Tobacco Control, 2008 “Quitting cigarettes completely or switching to smokeless tobacco: do U.S. Data replicate the Swedish Results” (from www.aaphp.org web site)	A38
A5	Fagerstrom K: The nicotine market: An attempt to estimate the nicotine intake from various sources and the total nicotine consumption in some countries . Nicotine & Tobacco Research, 7:3, pp 343-350, June 2005.	A41
A6	Godshall E-mail 12/29/09 5:12PM Godshall used the formula and data from the Fagerstrom paper to estimate the percentages of nicotine intake in the USA from cigarettes, smokeless and NRT products	A49
A7	Rodu B, Godshall WT: Tobacco harm reduction: an alternative cessation strategy for inveterate smokers . Harm Reduction Journal 3:37 (2006)	A53
A8	http://www.harmreduction.org	A76
A9	Rodu B, Cole P: Nicotine Maintenance for inveterate smokers . Technology, Vol 6, pp 17-21, 1999.	A81
A10	Petition by the NY state health commissioner to FDA requesting that NRT products be made more readily available and at lower cost. Downloaded from	A87
A11	O’Connor RJ, Hyland A, Giovino G, Fong GT, Cummings KM. Smoker awareness of and beliefs about supposedly less harmful tobacco products . Am J Prev Med 2005; 29: 85-90 Abstract only	A89
A12	Cummings KM. Informing Consumers about the Relative Health Risks of Different Nicotine Delivery Products , presented at the National Conference on Tobacco or Health, New Orleans, LA, 2001.	A90
A13	O’Connor RJ, MCNEILL A, BORLAND R, et al. Smokers’ beliefs about the relative safety of other tobacco products: findings from the ITC Collaboration . Nic & Tob Res 2007; 9: 1033-42. Abstract only	A100
A14	Altria comment to FDA Dockets Management 12/22/2009 requesting that FDA recognize that smokeless tobacco products are less hazardous than cigarettes	A101
A15	Gartner CE, Hall WD, Vos T, Bertram MY, Wallace AL, Limm SS: Assessment of Swedish snus for tobacco harm reduction: an epidemiological modeling study . Abstract only	A102

Attachment Set A: Harm Reduction References

Table of Contents

A16	Ramstrom LM, Foulds J: Role of snus in initiation and cessation of tobacco smoking in Sweden. Tobacco Control 15:210-214 2006	A103
A17	Smoking-attributable mortality, Years of Potential Lief Lost and Productivity Losses – United States, 200-2004. MMWR Weekly November 14, 2008 57(45); 1226-1228	A108
A18	Smoking continues gradual decline among U.S. teens, smokeless tobacco threatens a comeback. Press release December 14, 2009 from the Monitoring the Future program at the University of Michigan.	A112
A19	Murrelle L et al: Hypotheses and fundamental study design characteristics for evaluating potential reduced-risk tobacco products. Part I: Heuristic. Regulatory Toxicology and Pharmacology (2009), doi:10.1016/j.yrph.2009.12.002	A119
A20	Pankow JF, Watanabe KH, Tocalino PL, Luo W; Austin DF: Calculated Caner Risks for Conventional and “Potentially Reduced Exposure Product” Cigarettes. Cancer Epidemiol Biomarkers Prev 16(3) pages 584-592 (2007).	A129
A21	The home page of the Tobacco Control Research Branch of the National Cancer Institute has, as its opening line, “The vision of the TCRB is a world free of tobacco use and related cancer and suffering.”	A138

For additional detail on contents of each item, see the Annotated Index to Attached Reference Materials toward the end of the Petition Document.

Attachment Set B: Electronic Cigarette References
Table of Contents **Page 1 of 2**

#	Item	Page
B1	Ben Thomas Group LLC: Study to Determine the Presence of TSNAs in NJOY Vapor. A report to Scottera, Inc, dba NJOY December 9, 2009. Ben Thomas Group, LLC, 11200 Westheimer Rd, Suite 900, Houston TX 77042	B1
B2	Experiences of Electronic Cigarette Users Suggests that These Could Be Life-Saving Devices and that They are Effective for Smoking Cessation. Commentary on Dr. Siegel’s tobacco policy blog	B24
B3	Judge Leon’s 1/14/2010 opinion ordering FDA to allow importation of Smoking Everywhere and NJOY E-cigarette products	B28
B4	New Jersey GASP report on Electronic Cigarettes (E-Cigarettes)	B36
B5	FDA Analysis and Responses to FDA Press Release	
B5a	News Events links to July 22, 2009 Press “to discuss potential health risks associated with electronic cigarettes.”	B41
B5b	July 22, 2009 press release transcript	B42
B5c	FDA E-cigarette laboratory analysis serving as basis for July 22 press conference	B54
B5d	Scientific Review of FDA Report- evaluation of FDA study prepared for NJOY	B58
B5e	Prominent Doctors Specializing in Tobacco Harm Reduction Question FDA Study- report by inLife	B65
B5f	AAPHP letter to Dr. Deyton	B66
B5g	Siegel M (Blog post 7/22/2009): Tobacco-Specific Carcinogens Found in Nicotine Replacement Products; Will Anti-Smoking Groups Call for Removal of these Products from the Market? Despite Laboratory Finding of Carcinogens in Nicotine Replacement Medications, FDA Fails to Hold Press Conference to Express Concern About Potential Dangers of Nicotine Replacement Products	B69
B5h	Siegel M (Blog post 7/30/2009): Comparison of Carcinogen Levels Shows that Electronic Cigarettes are Much Safer than Conventional Ones	B71
B5i	Siegel M (from Blog): List of Identified, Known Carcinogens in Electronic Cigarettes vs. Conventional Cigarette	B73
B6	Liquid and Vapor Analyses	
B6a	Safety Report on the Ruyan E-cigarette Cartridge and Inhaled Aerosol	B74
B6b	e- cigs.co.uk – study of one bottle of “e-juice XX High 36mg/ml	B86

Attachment Set B: Electronic Cigarette References
Table of Contents **Page 2 of 2**

B6c	InLife (Alliance Technologies) – two studies of Regal Cartridge	B89
B6d	esmoke.net – Precision Testing Labs studies of eSmoke LLC liquid	B103
B6e	Totally Wicked/TECC – due diligence GC-MS analysis of 3 nicotine cartridges	B108
B6f	Gamucci – due diligence GC-MS analysis of 4 nicotine cartridges	B111
B6g	Instead – due diligence GC-MS analysis of 2 nicotine cartridges and vapor	B133
B6h	SuperSmoker – lab analysis of the vapor from 20 SuperSmoker cigarettes, cigars and cartridges	B137
B6i	Propylene Glycol Studies – a Vapers Club review of the literature	B142
B6j	Siegel M (from Blog): No tobacco-specific nitrosamines or diethylene glycol detected in inLife electronic cigarettes: Do anti-smoking groups still want ex-smokers to return to the real thing?	B145

For additional detail on contents of each item, see the Annotated Index to Attached Reference Materials toward the end of the Petition Document.

Attachment C: NRT Product References
Table of Contents **Page 1 of 1**

#	Item	Page
C1	Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P: Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis . BMJ 338:b1024 2009	C1
C2	Waldum HL et al: Long term effects of inhaled nicotine . Life Sci. 58(16) 1339-46	C11
C3	Murray RP, Connett, JE, Zapawa M: Does nicotine replacement therapy cause cancer? Evidence from Lung Health Study	C12
C4	OSSIP DJ et al: Adverse effects with use of nicotine replacement therapy among quitline clients	C14
C5	Sumner II W: Estimating the health consequences of replacing cigarettes with nicotine inhalers	C16
C6	Siegel M (from Blog): New study shows that at least two-thirds of patients receiving placebo in “double blind” NRT trials know that they are receiving placebo	C17
C7	Siegel M (from Blog): Effectiveness of nicotine replacement therapy needs to be re-examined	C19

For additional detail on contents of each item, see the Annotated Index to Attached Reference Materials toward the end of the Petition Document.